{"id":751388,"date":"2023-04-26T10:01:19","date_gmt":"2023-04-26T14:01:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/"},"modified":"2023-04-26T10:01:19","modified_gmt":"2023-04-26T14:01:19","slug":"menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/","title":{"rendered":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board"},"content":{"rendered":"
\n

JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (\u201cEntera\u201d or the \u201cCompany\u201d) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB).<\/p>\n

\u201cWe are thrilled to welcome Dr. Goldstein, a world-renowned leader in menopause and women\u2019s health, to our CSAB and look forward to working with him along with our esteemed endocrinology experts at this critical time for our EB613 program. Gynecologists remain primary care for the millions of women in or post-menopause globally and the importance of actively managing bone health is paramount to their well-being. As potentially the first oral osteoanabolic therapy for post-menopausal women, EB613 is being developed to fulfill this promise,\u201d stated Miranda Toledano, Chief Executive Officer of Entera.<\/p>\n

\u201cOsteoporosis is becoming one of the biggest medical problems of our aging population. In the U.S. for hip fractures alone, 21% of women who suffer a hip fracture will be dead within a year even after it is surgically repaired. Without surgery, the one-year mortality rate is about 70%1<\/sup>. Unfortunately, much of the undertreatment of osteoporosis and the missed opportunity to reduce fractures stems from lack of oral anabolic agents. The fact that such agents require injection (either daily or monthly) causes large numbers of women to go under treated. An oral PTH analogue would be extremely useful in helping so many of these women,\u201d stated Dr. Steven R. Goldstein.<\/p>\n

\n About Entera Bio<\/strong>\n <\/p>\n

Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a daily mini tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company\u2019s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development. Both EB612 and EB613 are being developed to address undertreated diseases which disproportionately afflict women. EB613 is the first oral, once daily mini tablet presentation of synthetic hPTH (1-34), (teriparatide), consisting of the exact same 34 amino acid sequence as daily subcutaneous teriparatide injection, Forteo\u00ae, a mainstay anabolic treatment which requires daily SC injections. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD\/biomarker) and secondary endpoints (BMD) in a dose dependent manner and was presented at the ASBMR 2021 Annual Conference. A phase 1 PK study of novel PTH formulations is planned for H1 2023 to ascertain feasibility of a new hypo candidate (a prior formulation had positive Phase 2a data announced in 2015 and published in JBMR 2019) and for another potential indication. For more information on Entera Bio, visit www.enterabio.com<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward Looking Statements<\/strong>\n <\/p>\n

Various statements in this press release are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cdesign,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwill,\u201d and \u201cwould,\u201d or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.<\/p>\n

Important factors that could cause actual results to differ materially from those reflected in Entera\u2019s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA\u2019s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera\u2019s agreement with Amgen; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera\u2019s product candidates; Entera\u2019s reliance on third parties to conduct its clinical trials; Entera\u2019s expectations regarding licensing, business transactions and strategic collaborations; Entera\u2019s operation as a development stage company with limited operating history; Entera\u2019s ability to continue as a going concern absent access to sources of liquidity; Entera\u2019s ability to obtain and maintain regulatory approval for any of its product candidates; Entera\u2019s ability to comply with Nasdaq\u2019s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera\u2019s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the \u201cCautionary Statements Regarding Forward-Looking Statements,\u201d \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of Entera\u2019s most recent Annual Report on Form 10-K filed with the SEC, as well as the company\u2019s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.<\/p>\n

_______________________________________<\/p>\n

\n 1<\/sup> Mundi S, Pindiprolu B, Simunovic N, Bhandari M.\u00a0Similar mortality rates in hip fracture patients over the past 31 years: a systematic review of RCTs<\/a>.\u00a0Acta <\/em>Orthopaedica<\/em>. 2014;85(1):54-9. doi:10.3109\/17453674.2013.878831<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

\n
Contact:\r\n\r\nEntera Bio:\r\nMs. Miranda Toledano\r\nChief Executive Officer\r\nEntera Bio\r\nEmail: miranda@enterabio.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (\u201cEntera\u201d or the \u201cCompany\u201d) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB). \u201cWe are thrilled to welcome Dr. Goldstein, a world-renowned leader in menopause and women\u2019s health, to our CSAB and look forward to working with him along with our esteemed endocrinology experts at this critical time for … <\/p>\n
Continue reading “Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751388","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (\u201cEntera\u201d or the \u201cCompany\u201d) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB). \u201cWe are thrilled to welcome Dr. Goldstein, a world-renowned leader in menopause and women\u2019s health, to our CSAB and look forward to working with him along with our esteemed endocrinology experts at this critical time for … Continue reading "Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T14:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board\",\"datePublished\":\"2023-04-26T14:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/\"},\"wordCount\":1120,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/\",\"name\":\"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=\",\"datePublished\":\"2023-04-26T14:01:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/","og_locale":"en_US","og_type":"article","og_title":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk","og_description":"JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (\u201cEntera\u201d or the \u201cCompany\u201d) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB). \u201cWe are thrilled to welcome Dr. Goldstein, a world-renowned leader in menopause and women\u2019s health, to our CSAB and look forward to working with him along with our esteemed endocrinology experts at this critical time for … Continue reading \"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T14:01:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board","datePublished":"2023-04-26T14:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/"},"wordCount":1120,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/","name":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=","datePublished":"2023-04-26T14:01:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTk5NCM1NTU4NDk3IzIwOTM3ODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/menopause-luminary-dr-steven-r-goldstein-joins-enteras-clinical-and-scientific-advisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera\u2019s Clinical and Scientific Advisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751388"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751388\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}